Drug Profile
Human glial restricted progenitor cells based therapeutics - Q Therapeutics
Alternative Names: Glial cell-based therapeutics - Q Therapeutics; hGRPs - Q Therapeutics; Q-CellsLatest Information Update: 13 Oct 2022
Price :
$50
*
At a glance
- Originator University of Utah
- Developer Drexel University College of Medicine; Johns Hopkins University; Q Therapeutics
- Class Cell therapies; Neuroprotectants; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Transverse myelitis
- Preclinical Amyotrophic lateral sclerosis; Multiple sclerosis; Spinal cord injuries; Stroke
Most Recent Events
- 28 Jan 2020 Preclinical development is ongoing for Amyotrophic lateral sclerosis, spinal cord injury and Demyelinating disorders in USA (Q Therapeutics pipeline, January 2020)
- 28 Jan 2020 Preclinical trials in Multiple sclerosis in USA (Parenteral) prior to January 2020 (Q Therapeutics pipeline, January 2020)
- 28 Jan 2020 Preclinical trials in Stroke in USA (Parenteral) prior to January 2020 (Q Therapeutics pipeline, January 2020)